《全日總結》恆指跌466點 阿里及美團挫逾6% 渣打績後偏好
杭州市監局就低價惡性競爭等問題約談科網企業,市場再度憂慮科網股監管問題,港股今日下跌。恆指高開24點後掉頭向下,曾跌572點一度低見20,050點,全日跌466點或2.26%,收20,156點;國指跌197點或2.78%,收6,885點;恆生科技指數跌221點或4.86%,收4,331點。大市全日成交總額增至1,296.41億元,滬、深港通南下交易分別淨流出2.95億及淨流入10.84億元人民幣。
科網股受壓,遭杭州市監局約談的美團(03690.HK)及餓了麼平台母公司阿里巴巴(09988.HK)各跌6.2%及6.1%,分別報176.3元及93.1元。騰訊(00700.HK)跌4.4%報306.8元,小米(01810.HK)跌5.1%報12.34元,京東(09618.HK)跌4.6%報233.8元。快手(01024.HK)及嗶哩嗶哩(09626.HK)各跌7.1%及6.5%。
京東健康(06618.HK)、明源雲(00909.HK)、汽車之家(02518.HK)及閱文(00772.HK)各跌7.5%至9%。手機相關股比亞迪電子(00285.HK)及瑞聲(02018.HK)各跌6.1%及4.9%,電訊設備股京信通信(02342.HK)跌4.7%。
消費股下滑,百威亞太(01876.HK)績後股價回吐8.2%報21.75元,九毛九(09922.HK)及泡泡瑪特(09992.HK)各跌6.6%及6.7%,潤啤(00291.HK)、青啤(00168.HK)、呷哺呷哺(00520.HK)及頤海(01579.HK)各跌3.6%至5.1%。汽車股小鵬(09868.HK)跌4.1%。體育用品股李寧(02331.HK)跌4.2%。醫藥股信達生物(01801.HK)、復星醫藥(02196.HK)、藥明生物(02269.HK)及中生製藥(01177.HK)各跌3%至3.6%。百濟神州(06160.HK)跌4.4%。
合景泰富(01813.HK)股價跌7%。龍湖(00960.HK)跌5.8%,碧桂園(02007.HK)及雅居樂(03383.HK)各跌逾4%,萬科(02202.HK)跌3.5%。物管股雅生活(03319.HK)、碧服(06098.HK)及華潤萬象(01209.HK)各跌4.7%、5.8%及7.8%。濠賭股新濠國際(00200.HK)、澳博(00880.HK)及美高梅中國(02282.HK)各跌4.1%至4.8%。
金融股方面,匯控(00005.HK)跌0.4%報49.4元,港交所(00388.HK)跌2.3%報359元。渣打(02888.HK)中期業績勝預期並宣布股份回購,股價倒升0.3%報56.05元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.